Canada Markets open in 4 hrs 59 mins

Atossa Therapeutics, Inc. (ATOS)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.8601+0.0361 (+4.38%)
At close: 04:00PM EDT
0.9459 +0.09 (+9.98%)
Pre-Market: 04:29AM EDT
Full screen
Loading interactive chart...
  • GlobeNewswire

    Atossa Therapeutics, Inc. to Attend the 24th Annual H.C. Wainwright Global Investment Conference

    SEATTLE, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology and infectious disease with a current focus on breast cancer and COVID-19, announced today that Kyle Guse, General Counsel & Chief Financial Officer will attend the 24th Annual H.C. Wainwright Global Investment Conference being held on September 12 – 14, 2022 at the Lotte New

  • GlobeNewswire

    Registration Now Open for Tribe Public’s Webinar Event "The Important Role For Inhalation Therapy In Oncology" Featuring The Management Team From Atossa Therapeutics on August 25, 2022

    Meet with Atossa’s CEO & Founder, Dr. Steven Quay, M.D., Ph.D. & Kyle Guse, GC & CFOSAN FRANCISCO, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology and infectious disease with a current focus on breast cancer and COVID-19, announces that Atossa’s CEO, Dr. Steven Quay, M.D., Ph.D., and Kyle Guse, GC & CFO will present at Tribe Public’

  • GlobeNewswire

    Atossa Therapeutics Appoints Dr. Paul Wabnitz to Its Scientific Advisory Board

    The Company Re-Appoints Drs. Mak Jawadekar, Per Hall, and Carl NovinaSEATTLE, Aug. 18, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) a clinical stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases with a current focus on breast cancer and COVID-19, today announces the appointment of Dr. Paul Wabnitz to its Scientific Advisory Board (SAB). The Company has also re-appointed Drs. Ma